furosemide | Horse Racing Free Tips

HISA To Fund Three Scientific Studies On The Use of Furosemide

Following a recommendation from its Furosemide Advisory Committee (FAC), the Horseracing Integrity and Safety Authority's Board of Directors approved $773,500 in grant funding for three scientific studies on the use of furosemide (also known as “Lasix”) to be conducted over the next two years by the Nationwide Children's Hospital, the University of Florida College of Veterinary Medicine and Washington State University, HISA said in a Wednesday release.

The studies will examine the 48-hour period before the start of a Covered Horserace, including the effects of furosemide on equine health and the integrity of competition. Researchers will be required to present final reports on their findings to the FAC on or before Jan. 31, 2026.

“The Furosemide Advisory Committee is grateful to the expert researchers who responded to our request for proposals and look forward to partnering with Nationwide Children's Hospital, the University of Florida College of Veterinary Medicine and Washington State University on this important research,” said FAC Chairman Dr. Scott Palmer, VMD. “The lifelong health and well-being of Thoroughbreds is our top priority. This work will help ensure we have policies in place to safeguard these remarkable animals and the integrity of the sport.”

Under the Horseracing Integrity and Safety Act, HISA is required to fund scientific research on the topic of furosemide to inform the FAC's future recommendations to the HISA Board on whether and how to amend their existing furosemide regulations.

A request for proposals was issued by HISA in August 2023. Out of those submitted, the following were recommended by the FAC and approved:

Examining Associations Between Furosemide Treatment & Racehorse Health and Welfare

Principal Investigator: Amanda Waller, Bsc, PhD, Research Scientist, Center for Clinical and Translational Research, Nationwide Children's Hospital
This study will examine the effects of race day furosemide treatment on the health and welfare of Thoroughbreds as well as their long-term racing performance. An analysis will be conducted to assess the association between pre-race furosemide administration and fatal injury, while also comparing the performance metrics–including lifetime earnings, career length, lifetime starts, starts per year, placings and average speed figures–of horses that raced exclusively on furosemide as 2-year-olds and horses that did not receive furosemide as juveniles.

Effects of Repeated Furosemide Administration on Electrolyte Homeostasis and Bone Density in Healthy Adult Exercising Thoroughbreds

Principal Investigator: SallyAnne L. DeNotta, DVM, PhD, DACVIM., Clinical Assistant Professor, Large Animal Medicine, University of Florida College of Veterinary Medicine
This study will examine the effects of repeated furosemide administration on electrolyte homeostasis, parathyroid response and urinary electrolyte excretion in exercising adult Thoroughbreds. The study will also examine the effects of repeated administration on bone density and strength using minimally invasive methods of measurement, including DEXA scan and OsteoProbe.

Does Pre-Race Administration of Furosemide to Thoroughbred Racehorses Prolong Their Racing Careers?

Principal Investigator: Warwick Bayly, BVSc, PhD, DACVIM, Professor, Department of Veterinary Clinical Sciences, Washington State University
This study will examine the impact of severe exercise-induced pulmonary hemorrhage (EIPH) on horses' careers and the health of the racing industry more broadly. In doing so, the study will assess whether regular furosemide treatment is associated with more career starts and greater longevity and the impact of banning furosemide for 2-year-olds on the duration of their careers and number of lifetime starts. The study will also seek to determine the extent to which severe EIPH impacts the number of subsequent starts, the periods between them and, when applicable, the time between the diagnosis of severe EIPH and retirement.

The post HISA To Fund Three Scientific Studies On The Use of Furosemide appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

HISA Releases Request For Furosemide Research Proposals

HISA released a request for proposals concerning research over the administration of furosemide to Thoroughbred racehorses during the 48-hour period before the start of a race, the organization said in a release late Tuesday.

This research is required as part of HISA's Congressional mandate. The conclusions will be used to guide HISA's Furosemide Advisory Committee in its recommendations to their Board on the next course of action regarding the administration of the drug.

Responses are due by Nov. 15 at 11:59 pm (ET). Questions pertaining to the process for submitting a response and final proposals can be directed to Dr. Jennifer Durenberger and/or Sam Reinhardt.

The post HISA Releases Request For Furosemide Research Proposals appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Research Proposals on Lasix will be Accepted by HISA Sept. 1

The Horseracing Integrity and Safety Authority called for potential researchers to prepare research proposals on the administration of furosemide, still commonly called Lasix in racing, to Thoroughbred racehorses during the 48-hour period before the start of a race, the organization said in a release Thursday evening. The call for proposals is expected to be released Sept. 1.

As the Authority was created by the Horseracing Integrity and Safety Act (HISA) of 2020, it is mandated by Congress to include at least one study on the use of furosemide. Included in the study is the effect of Lasix on equine health and the integrity of competition while using the medication.

Study conclusions will be used to guide the Authority's Furosemide Advisory Committee (FAC) in its recommendations to the Authority's Board. In evaluating applications, the FAC will pay particular attention to the impact of the proposed work as it applies to racing in North America.

Any questions should be directed to feedback@hisaus.org and titled “HISA research.”

The post Research Proposals on Lasix will be Accepted by HISA Sept. 1 appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

HISA’s Lasix Advisory Committee Set

Edited Press Release

The Horseracing Integrity and Safety Authority (HISA) announced the members of an Advisory Committee which has been convened to oversee a three-year study on the use of furosemide (also known as “Lasix”) on horses during the 48-hour period before the start of a Covered Horserace, including the effect on equine health and the integrity of competition.

The establishment of this Advisory Committee for the study of furosemide administration and the requirements of the study are specifically mandated and set forth in the Horseracing Integrity and Safety Act. The HISA Board of Directors delegated its authority to select the Advisory Committee members to HISA's Anti-Doping and Medication Control (ADMC) Committee who did so based on the members' relevant expertise. The Advisory Committee will oversee the process of issuing a Request for Proposal to conduct the research, reviewing grant applications from academic researchers and allocating grant funding for the study.

When the independent scientific research has been completed and published, it will be presented to the Advisory Committee who will then relay the findings and their recommendations to the HISA Board of Directors.

The Furosemide Advisory Committee is comprised of the following members:

Emma Adam, DVM, Ph.D., is a veterinarian with over 24 years of racing experience in the United States, United Kingdom, France and Australia. She is board-certified in equine medicine from Texas A&M University and in surgery from the New Bolton Center at the University of Pennsylvania. Dr. Adam also received her Ph.D. in musculoskeletal science from the University of Kentucky's Gluck Equine Research Center.
Alan Foreman is Chairman of the Thoroughbred Horsemen's Association (THA) and Vice-Chairman of the Racing Medication and Testing Consortium (RMTC). Foreman is considered one of the leading racing law and equine attorneys in the United States and is an expert on medications used in horse racing.
Scott Hay, DVM, is a veterinarian at Teigland, Franklin and Brokken, where he focuses on lameness, performance evaluations and purchase examinations. He also serves on the RMTC's Scientific Advisory Committee. Dr. Hay previously served as President of the American Association of Equine Practitioners (AAEP) and as a member of the Grayson-Jockey Club's Scientific Advisory Committee.
Ted Hill, VMD, is a racing steward for The Jockey Club with more than 23 years of experience. He previously served as Chief Veterinarian for the New York Racing Association (NYRA). Dr. Hill received his VMD from the University of Pennsylvania.
Rob Holland, DVM, Ph.D., is a respiratory and infectious disease specialist in Lexington, Kentucky and partner at Holland Management Services, Inc., a consulting practice offering solutions in outcomes research and veterinary medicine. Dr. Holland has worked with the Kentucky Horse Racing Commission (KHRC) and is an expert in equine drug testing processes.
Heather Knych, DVM, Ph.D., DACVCP, is a Professor of Clinical Veterinary Pharmacology and Head of the Pharmacology Section at the K.L. Maddy Equine Analytical Chemistry Pharmacology Laboratory at the School of Veterinary Medicine at the University of California, Davis. Dr. Kynch is board-certified in Clinical Veterinary Pharmacology and has an extensive publication record in the areas of pharmacokinetics and pharmacodynamics. She received her DVM and Ph.D. in Pharmacology and Toxicology from the University of California, Davis, where she also conducted her residency in Veterinary Pharmacology.
Ryan Murphy is the Executive Director for the Partnership for Clean Competition (PCC), the leading anti-doping research organization dedicated to the protection of clean athletes. Prior to joining the PCC, Murphy served as Program Officer with the Sports Diplomacy division at the U.S. Department of State and prior to that as Senior Manager for Sport & Competition for Special Olympics International. Murphy has also worked as an International Doping Control Officer for International Doping Tests & Management. In addition to his work at the PCC, Murphy serves as an Adjunct Professor for the Sports Industry Management Master's program at Georgetown University.
Foster Northrop, DVM, is a practicing racetrack veterinarian with more than 35 years of industry experience. He has served on the boards of the KHRC and American Veterinary Medical Association (AVMA), as well as the RMTC's Scientific Advisory Committee.
Scott Palmer, VMD, is a former President of the AAEP and the American Board of Veterinary Practitioners (ABVP). He also chaired the New York Task Force for Racehorse Health and Safety from 2011 to 2013 and served as a clinician and referral surgeon at the New Jersey Equine Clinic for 38 years. He is currently a member of the RMTC's Scientific Advisory Committee, the Horseracing Testing Laboratory Committee, the Association of Racing Commissioners International's (ARCI) Drug Testing and Standards Committee and the ARCI's Equine Welfare and Veterinarians Committee.
N. Edward Robinson, BVetMed, Ph.D., is a nationally recognized veterinarian, academic and researcher who spent nearly 50 years at Michigan State University's College of Veterinary Medicine, during which he spent more than 20 years as the Matilda R. Wilson Professor of Large Animal Clinical Sciences. Dr. Robinson has spent his career researching lung disease in horses. He received his veterinary degree from the Royal Veterinary College in London and a Ph.D. from University of California, Davis.
Corinne Sweeney, DVM (HIWU Appointment), is an American College of Veterinary Internal Medicine (ACVIM) specialist and has spent the past 44 years at the University of Pennsylvania School of Veterinary Medicine. She has served as a member of the Pennsylvania State Horse Racing Commission since 2008 and previously served as Chair of the ARCI in 2019. She is a certified Organizational Ombuds Practitioner and has served as the Penn Vet Ombuds since 2015.

The post HISA’s Lasix Advisory Committee Set appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post